BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 9293187)

  • 1. DNA gyrase, topoisomerase IV, and the 4-quinolones.
    Drlica K; Zhao X
    Microbiol Mol Biol Rev; 1997 Sep; 61(3):377-92. PubMed ID: 9293187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
    Chen CR; Malik M; Snyder M; Drlica K
    J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase IV, not gyrase, decatenates products of site-specific recombination in Escherichia coli.
    Zechiedrich EL; Khodursky AB; Cozzarelli NR
    Genes Dev; 1997 Oct; 11(19):2580-92. PubMed ID: 9334322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
    Hooper DC
    Clin Infect Dis; 1998 Aug; 27 Suppl 1():S54-63. PubMed ID: 9710672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.
    Aldred KJ; Schwanz HA; Li G; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
    ACS Chem Biol; 2013 Dec; 8(12):2660-8. PubMed ID: 24047414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase IV is a target of quinolones in Escherichia coli.
    Khodursky AB; Zechiedrich EL; Cozzarelli NR
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11801-5. PubMed ID: 8524852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial action of quinolones: from target to network.
    Cheng G; Hao H; Dai M; Liu Z; Yuan Z
    Eur J Med Chem; 2013 Aug; 66():555-62. PubMed ID: 23528390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
    Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
    Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The twisted 'life' of DNA in the cell: bacterial topoisomerases.
    Luttinger A
    Mol Microbiol; 1995 Feb; 15(4):601-6. PubMed ID: 7783632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of plasmid-mediated quinolone resistance.
    Tran JH; Jacoby GA
    Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5638-42. PubMed ID: 11943863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mode of action of fluoroquinolones.
    Hooper DC
    Drugs; 1999; 58 Suppl 2():6-10. PubMed ID: 10553698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus.
    Tanaka M; Onodera Y; Uchida Y; Sato K; Hayakawa I
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2362-6. PubMed ID: 9371334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrase-quinolone-DNA ternary complex.
    Hiasa H; Shea ME
    J Biol Chem; 2000 Nov; 275(44):34780-6. PubMed ID: 11053451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode of action of the new quinolones: new data.
    Hooper DC; Wolfson JS
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):223-31. PubMed ID: 1650698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
    Fournier B; Hooper DC
    Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.
    Heddle JG; Lu T; Zhao X; Drlica K; Maxwell A
    J Mol Biol; 2001 Jun; 309(5):1219-31. PubMed ID: 11399091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.
    Kumagai Y; Kato JI; Hoshino K; Akasaka T; Sato K; Ikeda H
    Antimicrob Agents Chemother; 1996 Mar; 40(3):710-14. PubMed ID: 8851598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.